In a welcome move, CME Group Cl A saw its Relative Strength Rating improve from 70 to 76 on Tuesday.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the best stocks tend to have an RS Rating north of 80 as they begin their biggest climbs. See if CME Group Cl A can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
The stock, which is on the IBD Big Cap 20 screen, is building a flat base with a 249.02 buy point. See if the stock can break out in volume at least 40% above average.
Taking a look at top and bottom line numbers, CME Group Cl A has posted two quarters of increasing earnings growth. Sales growth has also moved higher over the same time frame. CME Group Cl A is expected to report its next quarterly numbers on or around Feb. 12.
The company holds the No. 4 rank among its peers in the Financial Services-Specialty industry group. Marex Group is the No. 1-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
